ScholarIQanswers from OpenAlex & ORCID
Yoon‐Koo Kang
ResearcherPublications, citations & collaboration network
Yoon‐Koo Kang is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Yoon‐Koo Kang have?
ScholarIQindexed works
Yoon‐Koo Kang has 863 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Yoon‐Koo Kang have?
ScholarIQcitation count
Yoon‐Koo Kang has 61,587 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Yoon‐Koo Kang?
ScholarIQh-index
Yoon‐Koo Kang has an h-index of 95 in OpenAlex.
What is the i10-index of Yoon‐Koo Kang?
ScholarIQi10-index
Yoon‐Koo Kang has an i10-index of 378 in OpenAlex.
What is the ORCID of Yoon‐Koo Kang?
ScholarIQorcid
The ORCID for Yoon‐Koo Kang is on the source record.
What is the OpenAlex record for Yoon‐Koo Kang?
ScholarIQopenalex
The OpenAlex for Yoon‐Koo Kang is on the source record.
What are the most-cited papers on Yoon‐Koo Kang?
ScholarIQmost cited works
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Eric Assénat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, Paolo Abada, Masatoshi Kudo
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Călin Cainap, Shukui Qin, Wen‐Tsung Huang, Ik Joo Chung, Hongming Pan, Ying Cheng, Masatoshi Kudo, Yoon‐Koo Kang, Pei‐Jer Chen, Han-Chong Toh, Vera Gorbunova, Ferry A.L.M. Eskens, Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, Saied El-Nowiem
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer
Noe Kyeong Kim, Young Suk Park, Dae Seog Heo, Cheolwon Suh, Sang Yong Kim, Keun Chil Park, Yoon‐Koo Kang, Dong Bok Shin, Heung Tae Kim, Hyo Jin Kim, Won Ki Kang, Chang In Suh, Yung‐Jue Bang
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
B. Sangro, Stephen L. Chan, Robin Kate Kelley, George Lau, Masatoshi Kudo, Wattana Sukeepaisarnjaroen, M. Yarchoan, Enrico N. De Toni, J. Furuse, Yoon‐Koo Kang, Peter R. Galle, Lorenza Rimassa, Alexandra Heurgué, Vincent C. Tam, Tu Van Dao, S.C. Thungappa, В. В. Бредер, Y. Ostapenko, María Reig, M. Makowsky, Michael J. Paskow, Charu Gupta, John F. Kurland, Alejandra Negro, Ghassan K. Abou‐Alfa, Sérgio Santos de Azevêdo, Maria Ignez Braghiroli, Gustavo Girotto, Arinilda Campos Bragagnoli, Ricardo Branco, Adilson Faccio, Andrea Moretto, Nils Gunnar Skare, Jamille Dutra, Luciana Viola, Karina Vianna, Fernando Meton, Cláudia Vaz de Melo Sette, Amanda Faulhaber, Vincent C. Tam, Félix Couture, Jim Biagi, Hélène Castel, Karen Mulder, Yoo‐Joung Ko, Kevin Zbuk, Stephen Welch, Annie Beaudoin, Alexandra Heurgué, Éric Assenat, Isabelle Archambeaud, David Tougeron, Jean‐Marie Péron, Marine Gilabert, Jean–Pierre Bronowicki, Stéphane Cattan, Jean‐Frédéric Blanc, Mohamed Bouattour, Jean–Marc Phelip, Valérie Boige, Pierre Michel, Anne-Claire Frin, Enrico N. De Toni, Marie‐Luise Berres, Arndt Vogel, Thomas Berg, Thomas J. Ettrich, Dirk Waldschmidt, H. Wedemeyer, Marcus‐Alexander Wörns, Michael Bitzer, Karl-Heinz Weiss, George Lau, Stephen L. Chan, Thomas Yau, Y. Tai, Ann Shing Lee, Satheesh Chiradoni Thungappa, Lokesh K. N, Vikas Sureshchand Ostwal, Kattimani Kiran Ashok, Sushant Mittal, Hari Om Goyal, Sankar Srinivasan, Ghanashyam Biswas, Mallavarapu Mohan, Sewanti Limaye, Nirav Asarawala, Lorenza Rimassa, Alfredo Falcone, Luca Gianni, Antonio Gasbarrini, Bruno Daniele, Antonio Avallone, Giovanni Luca Frassineti, Fausto Roila, Masatoshi Kudo, Tomokazu Kawaoka, Manabu Morimoto, Yasuhiro Takikawa
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
Narikazu Boku, Min‐Hee Ryu, Ken Kato, Hyun Cheol Chung, Keiko Minashi, K.-W. Lee, H. Cho, Won Ki Kang, Yoshito Komatsu, Masahiro Tsuda, Kensei Yamaguchi, Hiroki Hara, Soichi Fumita, Mizutomo Azuma, L.-T. Chen, Yoon‐Koo Kang